This place is about more than a pharmaceutical career. It’s about making a real difference in the lives of patients. That’s why we’re here. That’s why you should maybe think about being here, too.Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Working to accomplish this mission is how we bring our vision to life. For us, that vision is the best possible therapeutics available to all patients with diseases of the endocrine system. We love how that sounds. And we really can’t wait to know how it feels.

National Institutes of Health

Bain Capital Life Sciences

Deep Track Capital

Driehaus Capital Management

Frazier Healthcare Partners

OrbiMed

Perceptive Advisors

RA Capital Management

Vivo Capital

5AM Ventures

Versant Ventures

Crinetics Pharmaceuticals

NexImmune is a pharmaceutical company focused on developing novel immunotherapeutics for the treatment of cancer and autoimmune diseases.

NexImmune

Mustang Bio is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer and rare genetic diseases.

Mustang Bio

Adaptimmune is a biotechnology company specializing in the development of T-cell therapies for the treatment of cancer.

Adaptimmune

HBM Holdings Ltd is a diversified holding company with interests in various industries, including pharmaceuticals and healthcare.

HBM Holdings Ltd

Dynavax Technologies Corp is a biopharmaceutical company focused on developing vaccines and immunotherapies for infectious diseases and cancer.

Dynavax Technologies Corp

Crinetics Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals, Inc.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

news_advanced

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Feb 12, 2024 11:26 PM	61d7bd65
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 12, 2024 11:26 PM	6baf9c9e
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Feb 12, 2024 11:26 PM	97a5d0b6
news basic	general	Feb 12, 2024 11:26 PM	65ea6270
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

COM:CRINETICS

Crinetics Pharmaceuticals

Last Close

53.34

26/07 20:00

Market Cap

4.01B

Beta: -

Volume Today

528.57K

Avg: -